Scinai Immunotherapeutics (SCNI) Other Non-Current Liabilities (2017 - 2025)
Scinai Immunotherapeutics (SCNI) posted Other Non-Current Liabilities of $3000.0 for Q2 2025, little changed sequentially from $3000.0 in Q4 2024, and little changed YoY from $3000.0 in Q2 2024.
Scinai Immunotherapeutics (SCNI) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Scinai Immunotherapeutics has reported Other Non-Current Liabilities for 8 years, with the latest figure at $3000.0 in Q2 2025.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $3000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $3000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $3000.0, down 96.88% from the prior year.
- Other Non-Current Liabilities was little changed at $3000.0 in Q2 2025 per SCNI's latest filing, from $3000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $5.3 million in Q4 2022 and troughed at $3000.0 in Q2 2024.
- A 4-year average of $1.0 million and a median of $96000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities tumbled 99.67% in 2024, then changed 0.0% in 2025.
- Over 4 years, Other Non-Current Liabilities stood at $5.3 million in 2022, then sank by 98.2% to $96000.0 in 2023, then slumped by 96.88% to $3000.0 in 2024, then changed by 0.0% to $3000.0 in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3000.0, $3000.0, and $3000.0 for Q2 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Scinai Immunotherapeutics | 11.72 Mn | -3.10 Bn | -1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Dec 31, 2023 | 96,000.00 |
| Sep 30, 2023 | 311,000.00 |
| Jun 30, 2023 | 902,000.00 |
| Mar 31, 2023 | 2.66 Mn |
| Dec 31, 2022 | 5.33 Mn |
| Dec 31, 2020 | -14.81 Mn |
| Sep 30, 2020 | -14.81 Mn |
| Jun 30, 2020 | 12.69 Bn |
| Mar 31, 2020 | 12.99 Bn |
| Dec 31, 2019 | 4.29 Mn |
| Sep 30, 2019 | 4.15 Mn |
| Jun 30, 2019 | 4.10 Mn |
| Mar 31, 2019 | 4.01 Mn |
| Dec 31, 2018 | 3.91 Mn |
| Sep 30, 2018 | 3.57 Mn |
| Jun 30, 2018 | 3.50 Mn |